₦airaland Forum

Thanks

Small investment brought good returns

It is well.

Ofemmanu1:
Hi, where you dey get the tips abeg?

My personal forecast. Thanks!

78'Vendsyssel - Esbjerg 1:1√

81'Haugesund - Bodo/Glimt 0:3√

Invest with wisdom and caution if you care:

The highest mountains above sea level are generally not the highest above the surrounding terrain. There is no precise definition of surrounding base, but Denali, Mount Kilimanjaro and Nanga Parbat are possible candidates for the tallest mountain on land by this measure. The bases of mountain islands are below sea level, and given this consideration Mauna Kea (4,207 m (13,802 ft) above sea level) is the world's tallest mountain and volcano, rising about 10,203 m (33,474 ft) from the Pacific Ocean floor. Ojos del Salado has the greatest rise on Earth: 13,420 m (44,029 ft) vertically to the summit from the bottom of the Atacama Trench, which is about 560 km (350 mi) away, although most of this rise is not part of the mountain.

The highest mountains are also not generally the most voluminous. Mauna Loa (4,169 m or 13,678 ft) is the largest mountain on Earth in terms of base area (about 2,000 sq mi or 5,200 km2) and volume (about 10,000 cu mi or 42,000 km3), although, due to the intergrade of lava from Kilauea, Hualalai and Mauna Kea, the volume can only be estimated based on surface area and height of the edifice.

Divergent views in the past with respect to including snowcaps or not meant that China had a different height from Nepal over Mount Everest. Not anymore!
The earthquake that occurred in Mount Everest in 2015 necessitates this harmonized quest.
The official height for Mount Everest is now 8,848.86metres.

2 doses will be needed 21days apart.

(Reuters) - Margaret Keenan, a 90-year-old grandmother from Britain, has become the first person in the world to receive the Pfizer COVID-19 vaccine outside of a trial following its rapid clinical approval.

An early riser, Keenan received the jab given by Matron May Parsons at her local hospital in Coventry, central England, on Tuesday morning at 0631 GMT, a week before she turns 91.

Britain began rolling out the COVID-19 vaccine developed by Pfizer and BioNTech on Tuesday, the first Western country to start vaccinating its general population in what was hailed as a decisive watershed in defeating the coronavirus.

The mass inoculation will fuel hope that the world may be turning a corner in the fight against a pandemic that has crushed economies and killed more than 1.5 million, although ultra-cold storage and tricky logistics will limit its use for now.

“I feel so privileged to be the first person vaccinated against Covid-19,” said Keenan.

“It’s the best early birthday present I could wish for because it means I can finally look forward to spending time with my family and friends in the New Year after being on my own for most of the year.”

Progress made

Have you hurriedly concluded that someone you've never seen smiling is unfriendly or wicked? Wait a minute you might be mistaken as such a person might have Moebius syndrome.
It is a rare congenital neurological disorder which is characterized by facial paralysis and the inability to move the eyes from side to side. Most people with Moebius syndrome are born with complete facial paralysis and cannot close their eyes or form facial expressions. Limb and chest wall abnormalities sometimes occur with the syndrome. People with Moebius syndrome have normal intelligence, although their lack of facial expression is sometimes incorrectly taken to be due to dullness or unfriendliness. It is named for Paul Julius Moebius, a German neurologist who first described the syndrome in 1888.

People with Moebius syndrome are born with facial paralysis and the inability to move their eyes laterally. Often, their upper lip is retracted due to muscle shrinkage. Occasionally, the cranial nerves V and VIII are affected. If cranial nerve VIII is affected, the person experiences hearing loss.

Other symptoms that sometimes occur with Moebius syndrome are:

-Limb abnormalities—clubbed feet, missing fingers or toes
-Chest-wall abnormalities (Poland syndrome)
-Crossed eyes (strabismus)
-Difficulty in breathing and/or in swallowing
-Corneal erosion resulting from difficulty in blinking

Children with Moebius syndrome may have delayed speech because of paralysis of muscles that move the lips, soft palate and tongue root. However, with speech therapy, most people with Moebius syndrome can develop understandable speech. Möbius syndrome has been associated with increased occurrence of the symptoms of autism. Some children with Moebius syndrome are mistakenly labeled as intellectually disabled because of their expressionless faces, strabismus and frequent drooling.

Treatment is supportive and in accordance with symptoms. If they have difficulty nursing, infants may require feeding tubes or special bottles to maintain sufficient nutrition. Physical, occupational, and speech therapy can improve motor skills and coordination and can lead to better control of speaking and eating abilities. Often, frequent lubrication with eye drops is sufficient to combat dry eye that results from impaired blinking. Surgery can correct crossed eyes, protect the cornea via tarsorraphy, and improve limb and jaw deformities. Sometimes called smile surgery by the media, muscle transfers grafted from the thigh to the corners of the mouth can be performed to provide the ability to smile. Although "smile surgery" may provide the ability to smile, the procedure is complex and can take twelve hours for each side of the face. Also, the surgery cannot be considered a "cure" for Moebius syndrome, because it does not improve the ability to form other facial expressions.
©

3 out of 5.
Greens to load later in the day.

Kickoff Time is 1p.m for Prishtina v Feronikeli

Success in view

Better games ahead today.

maxwell530:
Fvck, Krasnodar cut this good games

Check your email for an important message before 2:30p.m today.

Some days are like that.

5/6 is a fair trial.

Skmoda360:
If it con be goalless nko? Anaye nA 50 50 jawre

62' Sevilla - Chelsea 0:2
54' Olivier Giroud goal

Luton - Norwich 3:1
2nd Half: 1:0
47' Collins J. (Penalty) [LUT]√

Skmoda360:
Chelsea can't beat Sevilla that's what I know

Chelsea is currently beating Sevilla @ that's what you know.

Skmoda360:
Chelsea can't beat Sevilla that's what I know

That is not for you to decide. Moreover the selection says at least a goal must be scored in the second half that is to say the second half will not be goalless.

What can be done to bring back quiz programmes such as:
(1) WHO WANTS TO BE A MILLIONAIRE?
and introduce a Nigerian version of
(2) WEAKEST LINK
(3) THE CUBE
(4) THE CHASE
(5) POINTLESS
(6) TIPPING POINT
(7) MASTERMINDS
( THE VOICE

I MEAN BRAINY PROGRAMMES TO IMPROVE THE IQ OF MOST TV VIEWERS AND AS WELL ENTERTAIN THEM?

For trial

dawnomike:
Why lab grown meat... Is the world short of livestocks? Sometimes, too much advancement in science and technology causes problems

Fear of zoonosis: don't forget COVID is faintly attributed to viruses emanating from bats and some induce that it's(bat) consumption might have been ann original cause.

YoonSung62:
China taking over

Singapore is not the same as China not even in location as they don't share border. Be more apt in your comments and they should be meaningful in line with the original thread.

Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19

By Jon Cohen


Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says, far above what many vaccine scientists were expecting just a few weeks ago.

More impressive still, Moderna’s candidate had 100% efficacy against severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group. The company today plans to file a request for emergency use authorization (EUA) for its vaccine with the U.S. Food and Drug Administration (FDA), and is also seeking a similar green light from the European Medicines
Agency.

The data released today bolster an interim report from the company two weeks ago that only analyzed 95 total cases but produced similarly impressive efficacy. “I would still like to see all of the actual data, but what we’ve seen so far is absolutely remarkable,” says Paul Offit, a vaccine researcher at the Children’s Hospital of Philadelphia who is a member of an independent committee of vaccine experts that advises FDA.

Moderna’s vaccine against SARS-CoV-2, the virus that causes COVID-19, relies on a novel technology that uses messenger RNA (mRNA) to code for a protein called spike that studs the surface of the pathogen. Pfizer and BioNTech have developed a similar mRNA vaccine against COVID-19 and also reported excellent results, with an efficacy of 95%, in the final analysis of their 45,000-person trial. In that study, which ended after 170 cases of COVID-19 were identified, only 10 severe cases occurred, and just one was in the vaccinated group.

Moderna and the Pfizer/BioNTech collaboration say their vaccines worked to about the same degree in all different groups, ethnicities, and genders. (More than 7000 participants in the Moderna trial were over age 65 and more than 5000 were under 65 but had diseases putting them at a higher risk of severe COVID-19; the study also included more than 11,000 people from communities of color.) That equal success is vital information for bodies trying to prioritize the use of the new vaccines, such as an advisory panel to the Centers for Disease Control and Prevention (CDC) that is meeting tomorrow. The committee’s recommendations influence CDC’s decisions about vaccine prioritization, but individual states come up with their own guidelines.

Moderna received $1 billion from the U.S. government’s Operation Warp Speed to help develop its mRNA vaccine. (Pfizer passed on such development money, but has signed an advanced purchase order for its vaccine with Warp Speed.) Moderna CEO Stéphane Bancel says all of the federal money went toward staging the clinical trials, and that without it, progress surely would have been delayed. Investors in May contributed another $1.3 billion to help the young company, which has no products on the market, build facilities to produce its vaccine.

Pfizer filed an EUA request for its vaccine last week, which led FDA to announce it will convene a meeting of its vaccine advisory committee to discuss the data in depth on 10 December. Bancel says FDA has told the company it might convene the committee again as early as 17 December to review its EUA application. He says the agency could issue an EUA 24 to 72 hours later.

Bancel imagines the Moderna vaccine, given its high efficacy against both mild and severe disease, will have the most impact if given to people at the greatest risk from SARS-CoV-2. “Give it to health care workers, give it to the elderly, give it to people with diabetes, overweight, heart disease,” he says. “A 25-year-old healthy man? Give him another vaccine.”

Moderna plans to charge $32 to $37 per dose of the vaccine in developed countries, Bancel says, but will have cheaper pricing for other parts of the world. The company is negotiating with the COVID-19 Vaccines Global Access Facility, a nonprofit that aims to reduce global vaccine inequities by purchasing and distributing approved products. “We want to have this vaccine available at a tiered price for low-income countries,” he says.
©